OBJECTIVE： To observe the clinical efficacy and safety of edaravone combined with cinepazide maleate in the treatment of cerebral vasospasm （CVS） after aneurismal subarachnoid hemorrhage （SAH）. METHODS： 66 patients with CVS after aneurismal SAH were selected and divided into control group and treatment group according to random number table， with 33 cases in each group. Control group was given Cinepazide maleate injection 320 mg added into 0.9％ Sodium chloride injection 500 mL， ivgtt， qd， on the basis of coventional treatment； treatment group was additionally given Edaravone injection 30 mg added into 0.9％ Sodium chloride injection 100 mL， ivgtt， bid. Both groups were treated for 14 d. Inflammatory factors （IL-6， TNF-α） levels， peak systolic velocity of middle cerebral artery （MCA Vp） before and after treatment， clinical efficacy and the occurrence of ADR were compared between 2 groups. RESULTS： Before treatment， there was no statistical significance in the levels of IL-6， TNF-α and MCA Vp between 2 groups （P＞0.05）； after treatment， the levels of IL-6 ， TNF-α and MCA Vp were decreased significantly in 2 groups， and the treatment group was significantly lower than the control group， with statistical significance （P＜0.05）. Total effective rate of treatment group was 90.91％， which was significantly higher than 63.64％ of control group， with statistical significance （P＜0.05）. No obvious ADR was found in 2 groups. CONCLUSIONS： Edaravone combined with cinepazide maleate has significant therapeutic efficacy on CVS after aneurismal SAH， and can effectively reduce the MCA Vp and inflammatory reaction with good safety.